TURNING POINT THERAPEUTICS I's ticker is TPTX and the CUSIP is 90041T108. A total of 213 filers reported holding TURNING POINT THERAPEUTICS I in Q2 2022. The put-call ratio across all filers is 3.08 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $3,559,000 | -31.2% | 47,300 | -75.5% | 0.00% | -100.0% |
| Q1 2022 | $5,176,000 | -36.0% | 192,773 | +13.7% | 0.00% | 0.0% |
| Q4 2021 | $8,086,000 | -20.7% | 169,541 | +10.4% | 0.00% | 0.0% |
| Q3 2021 | $10,198,000 | -1.8% | 153,520 | +15.3% | 0.00% | 0.0% |
| Q2 2021 | $10,384,000 | +66.0% | 133,114 | +101.3% | 0.00% | 0.0% |
| Q1 2021 | $6,256,000 | -9.9% | 66,138 | +16.0% | 0.00% | 0.0% |
| Q4 2020 | $6,946,000 | +35.7% | 57,016 | -2.7% | 0.00% | 0.0% |
| Q3 2020 | $5,117,000 | +43.3% | 58,584 | +6.0% | 0.00% | 0.0% |
| Q2 2020 | $3,571,000 | +639.3% | 55,276 | +411.6% | 0.00% | – |
| Q1 2020 | $483,000 | -24.8% | 10,805 | +4.8% | 0.00% | – |
| Q4 2019 | $642,000 | +89.4% | 10,312 | +14.3% | 0.00% | – |
| Q3 2019 | $339,000 | +208.2% | 9,025 | +233.0% | 0.00% | – |
| Q2 2019 | $110,000 | – | 2,710 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| venBio Partners LLC | 708,233 | $44,116,000 | 18.91% |
| Corriente Advisors, LLC | 285,000 | $17,753,000 | 9.54% |
| Cormorant Asset Management, LP | 3,396,650 | $211,577,000 | 8.44% |
| Opaleye Management Inc. | 340,500 | $21,210,000 | 4.16% |
| Orbimed Advisors | 2,745,327 | $171,006,000 | 2.44% |
| Parkman Healthcare Partners LLC | 101,434 | $6,318,000 | 1.82% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 35,000 | $2,179,000 | 0.78% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 366,000 | $22,798,000 | 0.73% |
| Artal Group S.A. | 300,000 | $18,687,000 | 0.72% |
| DAFNA Capital Management LLC | 30,408 | $1,894,000 | 0.65% |